Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consort

[1]  Trevor J Pugh,et al.  Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders. , 2018, Cancer genetics.

[2]  S. Kantarci,et al.  Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. , 2018, Cancer genetics.

[3]  M. Slovak,et al.  Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. , 2018, Cancer genetics.

[4]  M. Slovak,et al.  Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative n , 2018, Cancer genetics.

[5]  S. Jhanwar,et al.  Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation , 2017, Leukemia & lymphoma.

[6]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[7]  Lina Shao,et al.  Genome-Wide Single-Nucleotide Polymorphism Array Analysis Improves Prognostication of Acute Lymphoblastic Leukemia/Lymphoma. , 2016, The Journal of molecular diagnostics : JMD.

[8]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[9]  S. Rajkumar,et al.  Updated Diagnostic Criteria and Staging System for Multiple Myeloma. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[10]  C. Harrison,et al.  Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. , 2015, Blood.

[11]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[12]  J. Biegel,et al.  Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. , 2014, Cancer genetics.

[13]  Y. Miyazaki,et al.  [Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[14]  Matthew S. Lebo,et al.  American College of Medical Genetics and Genomics technical standards and guidelines: microarray analysis for chromosome abnormalities in neoplastic disorders , 2013, Genetics in Medicine.

[15]  J. Korbel,et al.  Criteria for Inference of Chromothripsis in Cancer Genomes , 2013, Cell.

[16]  Sean Davis,et al.  Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma. , 2013, Cancer research.

[17]  A. Kemper,et al.  An approach to family-centered coordinated co-management for individuals with conditions identified through newborn screening , 2013, Genetics in Medicine.

[18]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[19]  E. Thorland,et al.  Towards an evidence‐based process for the clinical interpretation of copy number variation , 2012, Clinical genetics.

[20]  David T. W. Jones,et al.  Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.

[21]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[22]  H. Barnard,et al.  The Children's Hospital, Los Angeles , 1915 .

[23]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[24]  S. South,et al.  Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. , 2015, Cancer genetics.

[25]  H. Hakonarson,et al.  Clinical utilization of high-resolution single nucleotide polymorphism based oligonucleotide arrays in diagnostic studies of pediatric patients with solid tumors. , 2012, Cancer genetics.

[26]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials , 2010 .

[27]  C. Pratt,et al.  St. Jude Children's Research Hospital. , 1997, Pediatric hematology and oncology.

[28]  Iscn.  An international system for human cytogenetic nomenclature , 1978 .